Company profile: Principia Biopharma
1.1 - Company Overview
Company description
- Provider of pre-clinical discovery and development of differentiated oral small-molecule therapies for inflammatory and autoimmune diseases and cancer, addressing significant unmet medical needs in immunology and oncology.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Principia Biopharma
BaroFold
HQ: United States
Website
- Description: Provider of protein therapeutics for immunology indications, focused on discovering, developing and commercializing protein biologics, some incorporating its proprietary PreEMT high-pressure folding technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BaroFold company profile →
Sitryx
HQ: United Kingdom
Website
- Description: Provider of cell metabolism–targeted, first-in-class, disease-modifying therapeutics in immuno-oncology and immuno-inflammation. Pipeline includes SYX-5219 for atopic dermatitis; SIT-052, an inhaled GLS1 inhibitor for pulmonary fibrosis and COPD that selectively breaks down senescent cells; SIT-033, a SIK2 inhibitor for ulcerative colitis; and SYX-1042 and SIT-047 for autoimmune indications (with Eli Lilly).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sitryx company profile →
Aclaris Therapeutics
HQ: United States
Website
- Description: Provider of dermatologic and immuno-inflammatory therapies R&D, using its KINect platform to discover small-molecule kinase inhibitors; conducts clinical trials; offers drug discovery and early development via Confluence Discovery Technologies; advancing ATI-1777 (topical JAK1/JAK3), ATI-2138 (oral ITK/JAK3), and Zunsemetinib/ATI-450 (oral MK2) for metastatic breast cancer and pancreatic ductal adenocarcinoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aclaris Therapeutics company profile →
ImmuPharma
HQ: United Kingdom
Website
- Description: Provider of drug discovery and development focused on pioneering, novel therapies in specialist therapeutic areas with few existing treatments. Pipeline includes P140 (Lupuzor) in Phase 3 for SLE, P140 in Phase 2/3 for CIDP, BioAMB (amphotericin-B variant) in preclinical for serious fungal infections, and BioCIN (vancomycin-based) in preclinical for severe bacterial infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmuPharma company profile →
Kither Biotech
HQ: Italy
Website
- Description: Provider of pharmaceutical drug development targeting chronic inflammatory diseases, with inhaled therapies such as KIT2014, a cAMP-modulating peptide add-on for cystic fibrosis that enhances CFTR function, reduces mucus, and limits airway inflammation, and KITCL27, an inhaled PI3K-inhibitor prodrug for idiopathic pulmonary fibrosis activated in target cells to minimize systemic side effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kither Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Principia Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Principia Biopharma
2.2 - Growth funds investing in similar companies to Principia Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Principia Biopharma
4.2 - Public trading comparable groups for Principia Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →